http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 16:07:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/McKesson+reports+cybersecurity+incident+affecting+its+information+systems/26997884.html <p>McKesson Corporation (NYSE: MCK) disclosed a cybersecurity incident affecting its information systems, discovered on August 25, 2026.</p><p>The company said an investigation is in its early stages. As of the date of the filing, McKesson has not determined that the incident is material or that it has had, or is reasonably likely to have, any material impact on the company, including its financial condition or results of operations.</p> http://www.streetinsider.com/Corporate+News/McKesson+reports+cybersecurity+incident+affecting+its+information+systems/26997884.html Fri, 28 Aug 2026 16:07:18 -0400 MCK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+25/26997835.html si-local-file:///var/storage/secattach/20260828/26997835.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+25/26997835.html Fri, 28 Aug 2026 16:05:00 -0400 MCK O.05049245 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+25/26997835.html si-local-file:///var/storage/secattach/20260828/26997835.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+25/26997835.html Fri, 28 Aug 2026 16:05:00 -0400 MCK O.05049245 http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Mergers+and+Acquisitions/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html <p>McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.</p> <p>Following completion of the transaction, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment. The deal remains subject to customary closing conditions, including regulatory clearances.</p> <p>Precision Medicine Group provides services to biotechnology and pharmaceutical companies, including biomarker intelligence, lab services, clinical research organization capabilities, market access consulting, and commercialization support.</p> <p>Brian Tyler, chair and chief executive officer of McKesson, said the acquisition "represents another meaningful step in advancing our oncology and multispecialty http://www.streetinsider.com/Corporate+News/McKesson+to+acquire+Precision+Medicine+Group+for+%242.25+billion/26971103.html Tue, 25 Aug 2026 08:00:58 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Press+Releases/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html <p class="bwalignc"> <i>Acquisition will enhance McKesson&apos;s clinical research and commercialization services</i> </p> <p> IRVING, Texas--(BUSINESS WIRE)-- McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global provider of clinical research and biopharma commercialization services. </p><p> McKesson will acquire Precision Medicine Group for approximately $2.25 billion<i>.</i> Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology &amp; Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. </p><p> “This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to http://www.streetinsider.com/Business+Wire/McKesson+Signs+Agreement+to+Acquire+Precision+Medicine+Group%2C+LLC/26971050.html Tue, 25 Aug 2026 08:00:00 -0400 A.32551614 MCK O.05049245 O.15639197 http://www.streetinsider.com/Analyst+PT+Change/McKesson+%28MCK%29+PT+Raised+to+%241%2C000+at+Barclays/26946318.html Barclays analyst Glen Santangelo raised the price target on McKesson (NYSE: MCK) to $1,000.00 (from $925.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/McKesson+%28MCK%29+PT+Raised+to+%241%2C000+at+Barclays/26946318.html Wed, 19 Aug 2026 03:21:41 -0400 MCK http://www.streetinsider.com/New+Coverage/RBC+Capital+Starts+McKesson+%28MCK%29+at+Sector+Perform/26946284.html <p>RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE: MCK) with a Sector Perform rating and a price target of $845.00.</p><p>The analyst comments: “Initiating with Sector Perform rating and $845 PT. We believe MCK's integrated model and specialty drug exposure position the company well to navigate IRA-driven revenue headwinds while biosimilar introductions represent margin accretion (~$250M OI by 2028). The pharmacy benefit channel poses steerage risks. We see near-term challenges to the RxTS segment OI growth targets as GLP-1 prior authorizations are pressured by coverage reductions, potentially representing 5-10% OI growth headwind, partially offsetting any outperformance in our base http://www.streetinsider.com/New+Coverage/RBC+Capital+Starts+McKesson+%28MCK%29+at+Sector+Perform/26946284.html Wed, 19 Aug 2026 03:07:12 -0400 MCK http://www.streetinsider.com/Analyst+Comments/RBC+Capital+Starts+McKesson+%28MCK%29+at+Sector+Perform/26946284.html <p>RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE: MCK) with a Sector Perform rating and a price target of $845.00.</p><p>The analyst comments: “Initiating with Sector Perform rating and $845 PT. We believe MCK's integrated model and specialty drug exposure position the company well to navigate IRA-driven revenue headwinds while biosimilar introductions represent margin accretion (~$250M OI by 2028). The pharmacy benefit channel poses steerage risks. We see near-term challenges to the RxTS segment OI growth targets as GLP-1 prior authorizations are pressured by coverage reductions, potentially representing 5-10% OI growth headwind, partially offsetting any outperformance in our base http://www.streetinsider.com/Analyst+Comments/RBC+Capital+Starts+McKesson+%28MCK%29+at+Sector+Perform/26946284.html Wed, 19 Aug 2026 03:07:12 -0400 MCK http://www.streetinsider.com/General+News/Evercore+reports+July+prescription+volumes+up+1.9%25+year-over-year/26910902.html <p>Investing.com -- Total prescription volumes in the United States increased 1.9% year-over-year in July and 1.6% month-over-month, reaching 575 million prescriptions, according to an Evercore analysis released today.</p><p>Branded prescriptions rose 3.7%, generic prescriptions climbed 1.6%, and specialty prescriptions jumped 8.5% compared to the same period last year. Mail order volumes increased 8.4% year-over-year in July, representing approximately 13.0% of total market share.</p><p>Medical specialty sales growth slowed to approximately 12% year-over-year in June, down from roughly 14% in May. This marks a decline from the 24% peak recorded in July 2025. Oncology followed a similar pattern, growing approximately 11% year-over-year compared http://www.streetinsider.com/General+News/Evercore+reports+July+prescription+volumes+up+1.9%25+year-over-year/26910902.html Wed, 12 Aug 2026 11:09:14 -0400 CVS MCK http://www.streetinsider.com/General+News/Evercore+reports+July+prescription+volumes+up+1.9%25+year-over-year/26910902.html <p>Investing.com -- Total prescription volumes in the United States increased 1.9% year-over-year in July and 1.6% month-over-month, reaching 575 million prescriptions, according to an Evercore analysis released today.</p><p>Branded prescriptions rose 3.7%, generic prescriptions climbed 1.6%, and specialty prescriptions jumped 8.5% compared to the same period last year. Mail order volumes increased 8.4% year-over-year in July, representing approximately 13.0% of total market share.</p><p>Medical specialty sales growth slowed to approximately 12% year-over-year in June, down from roughly 14% in May. This marks a decline from the 24% peak recorded in July 2025. Oncology followed a similar pattern, growing approximately 11% year-over-year compared http://www.streetinsider.com/General+News/Evercore+reports+July+prescription+volumes+up+1.9%25+year-over-year/26910902.html Wed, 12 Aug 2026 11:09:14 -0400 CVS MCK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+10++Filed+by%3A+Lerman+Bradley+E/26904774.html si-local-file:///var/storage/secattach/20260811/26904774.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MCKESSON+CORP+++++++++++++For%3A+Aug+10++Filed+by%3A+Lerman+Bradley+E/26904774.html Tue, 11 Aug 2026 14:06:00 -0400 MCK O.05049245